ASRT · CIK 0001808665 · operating
Assertio Holdings is a specialty pharmaceutical company that develops and commercializes products for pain management, rheumatologic conditions, seizure disorders, and chemotherapy-related side effects. The company's portfolio includes INDOCIN (indomethacin) for rheumatoid arthritis and related conditions; CAMBIA and SPRIX, both NSAIDs for migraine and moderate to moderately severe pain respectively; Otrexup (methotrexate auto-injector) for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriasis; Sympazan (clobazam) for Lennox-Gastaut syndrome; and ROLVEDON (pegfilgrastim) for reducing febrile neutropenia risk in chemotherapy patients. The company operates primarily in the United States market.
Assertio Holdings operates with a lean organizational structure of 58 full-time employees and maintains headquarters in Lake Forest, Illinois. The company was incorporated in Delaware in 2020, following a corporate reorganization from its predecessor entity Assertio Therapeutics, Inc. With a market capitalization of approximately $100 million, the company focuses on commercializing established pharmaceutical products rather than pipeline development. The company's revenue is generated through sales of its branded specialty pharmaceutical products across multiple therapeutic categories.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.23 | $-0.23 | +95.1% | |
| 2023 | $-4.67 | $-4.67 | -330.0% | |
| 2022 | $2.03 | $2.33 | +6866.7% | |
| 2021 | $-0.03 | $-0.03 | +88.9% | |
| 2020 | $-0.27 | $-0.27 | — |